Long-term efficacy and tolerability of abdominal once-yearly histrelin acetate subcutaneous implants in patients with advanced prostate cancer.

Woolen S, Holzmeyer C, Nesbitt E, Siami PF

Prostate cancer4 Dec 2014Cited by 5 (Europe PMC)

PMID25548680PMCIDPMC4274828DOI10.1155/2014/490315PepBankPUB-25548680

Summary

Objectives. Long-term assessment of the efficacy and tolerability of subcutaneous abdominal histrelin acetate implants that have been inserted for more than two years. Materials and Methods. Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant. Results. Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively. Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years. The testosterone levels remained significantly less than baseline (P < 0.05). Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively. The mean serum PSA was significantly greater than baseline during these years (P < 0.05). Eight patients (7.1%) experienced minor, but not serious, adverse events from the histrelin acetate. Conclusion. Subcutaneous abdominal histrelin acetate implants are an effective long-term and well-tolerated administration method for treating patients with advanced prostate cancer.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
During long-term histrelin treatment for advanced prostate cancer, 6 patients (5.3%) had androgen-independent progression.
In plain wordsDuring long-term histrelin treatment for prostate cancer, 6 patients (5.3%) had androgen-independent progression.
Peptide
Histrelin
Outcome
Not applicableAndrogen-independent progression
Study
n = 113
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with androgen-independent progression
6 patients
long-term follow-up
Patients with androgen-independent progression
5.3%
long-term follow-up
Source sentences
Summary
Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868006
02HumanObservational studySafety outcome
In patients receiving histrelin acetate implants for advanced prostate cancer, 8 (7.1%) experienced minor, but not serious, adverse events.
In plain wordsIn prostate cancer patients receiving histrelin, 8 (7.1%) had minor, but not serious, adverse events.
Peptide
Histrelin
Outcome
Not applicableMinor adverse events
Study
n = 113
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with minor adverse events
8 patients
113 patients
Patients with minor adverse events
7.1%
113 patients
Source sentences
Summary
Eight patients (7.1%) experienced minor, but not serious, adverse events from the histrelin acetate.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868010
03HumanObservational studyEfficacy outcome
In patients followed long term after histrelin implants for advanced prostate cancer, mean serum PSA rose to 35.0 µg/L (n = 22) at 3 years, significantly above baseline (P < 0.05); the source tied the rise to androgen-independent progression in six patients.
In plain wordsIn men with a histrelin implant, average PSA rose to 35.0 µg/L at 3 years, which the report tied to cancer progression in six men.
Peptide
Histrelin
Outcome
IncreaseMean PSA at 3 years
Study
n = 22
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Measurements
Mean serum PSA
35 µg/L
3 years, n = 22
Source sentences
Summary
Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean serum PSA was significantly greater than baseline during these years (P < 0.05).
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868007
04HumanObservational studyEfficacy outcome
In patients followed long term after histrelin implants for advanced prostate cancer, mean serum PSA rose to 30.7 µg/L (n = 13) at 4 years, significantly above baseline (P < 0.05); the source tied the rise to androgen-independent progression in six patients.
In plain wordsIn men with a histrelin implant, average PSA rose to 30.7 µg/L at 4 years, which the report tied to cancer progression in six men.
Peptide
Histrelin
Outcome
IncreaseMean PSA at 4 years
Study
n = 13
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 4 yearsAs given in this study (human).
Measurements
Mean serum PSA
30.7 µg/L
4 years, n = 13
Source sentences
Summary
Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean serum PSA was significantly greater than baseline during these years (P < 0.05).
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868008
05HumanObservational studyEfficacy outcome
In patients followed long term after histrelin implants for advanced prostate cancer, mean serum PSA rose to 132.9 µg/L (n = 8) at 5 years, significantly above baseline (P < 0.05); the source tied the rise to androgen-independent progression in six patients.
In plain wordsIn men with a histrelin implant, average PSA rose to 132.9 µg/L at 5 years, which the report tied to cancer progression in six men.
Peptide
Histrelin
Outcome
IncreaseMean PSA at 5 years
Study
n = 8
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · subcutaneous · 5 yearsAs given in this study (human).
Measurements
Mean serum PSA
132.9 µg/L
5 years, n = 8
Source sentences
Summary
Six patients (5.3%) had androgen-independent progression when followed up on the long term, increasing the mean serum PSA at 3, 4, and 5 years to 35.0 µg/L (n = 22), 30.7 µg/L (n = 13), and 132.9 µg/L (n = 8), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The mean serum PSA was significantly greater than baseline during these years (P < 0.05).
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868009
06HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, 92.1% had serum testosterone ≤30 ng/dL at 24 weeks.
In plain wordsIn prostate cancer patients receiving histrelin, 92.1% had testosterone ≤30 ng/dL at 24 weeks.
Peptide
Histrelin
Outcome
Not applicableTestosterone ≤30 ng/dL at 24 weeks
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Patients with serum testosterone ≤30 ng/dL at 24 weeks
92.1%
patients with advanced prostate cancer after first implant
Source sentences
Summary
Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868001
07HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving the histrelin implant, 92.1% and 91.8% had serum testosterone ≤30 ng/dL at 24 and 48 weeks after the first implant, respectively.
In plain wordsIn prostate cancer patients with a histrelin implant, 92.1% had testosterone ≤30 ng/dL at 24 weeks and 91.8% at 48 weeks.
Peptide
Histrelin
Outcome
Not applicableTestosterone ≤30 ng/dL at 24 and 48 weeks
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 24 and 48 weeksAs given in this study (human).
Measurements
Patients with testosterone ≤30 ng/dL
92.1%
24 weeks after first implant
Patients with testosterone ≤30 ng/dL
91.8%
48 weeks after first implant
Source sentences
Summary
Following insertion of the first implant, 92.1% and 91.8% of patients had a serum testosterone level of ≤30 ng/dL at 24 and 48 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868002
08HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, testosterone remained <30 ng/dL in 96% at two years.
In plain wordsIn prostate cancer patients receiving histrelin, testosterone remained <30 ng/dL in 96% at two years.
Peptide
Histrelin
Outcome
Not applicableTestosterone <30 ng/dL at two years
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · two yearsAs given in this study (human).
Measurements
Patients with testosterone <30 ng/dL
96%
two years
Source sentences
Summary
Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868003
09HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, testosterone remained <30 ng/dL in 100% at 3 years.
In plain wordsIn prostate cancer patients receiving histrelin, testosterone remained <30 ng/dL in 100% at 3 years.
Peptide
Histrelin
Outcome
Not applicableTestosterone <30 ng/dL at 3 years
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Measurements
Patients with testosterone <30 ng/dL
100%
3 years
Source sentences
Summary
Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868004
10HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, testosterone remained significantly below baseline (P < 0.05).
In plain wordsIn prostate cancer patients receiving histrelin, testosterone remained significantly below baseline.
Peptide
Histrelin
Outcome
DecreaseTestosterone change from baseline
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
The testosterone levels remained significantly less than baseline (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868005
11HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, testosterone remained <30 ng/dL in 100% at 4 years.
In plain wordsIn prostate cancer patients receiving histrelin, testosterone remained <30 ng/dL in 100% at 4 years.
Peptide
Histrelin
Outcome
Not applicableTestosterone <30 ng/dL at 4 years
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 4 yearsAs given in this study (human).
Measurements
Patients with testosterone <30 ng/dL
100%
4 years
Source sentences
Summary
Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868012
12HumanObservational studyEfficacy outcome
In patients with advanced prostate cancer receiving histrelin, testosterone remained <30 ng/dL in 100% at 5 years.
In plain wordsIn prostate cancer patients receiving histrelin, testosterone remained <30 ng/dL in 100% at 5 years.
Peptide
Histrelin
Outcome
Not applicableTestosterone <30 ng/dL at 5 years
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 5 yearsAs given in this study (human).
Measurements
Patients with testosterone <30 ng/dL
100%
5 years
Source sentences
Summary
Serum testosterone levels remained at <30 ng/dL for 96% of patients at two years and for 100% of patients at 3, 4, and 5 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Retrospective data collected over a six-year period at a single center from charts of 113 patients who received the subcutaneous abdominal histrelin acetate implant.
Show in the study text Report a problemFND-2554868013

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.